Loading
Gamma Biotherapeutics
Gamma Biotherapeutics is a Portland company whose antibody, M3T01, blocks Fas ligand, a molecule many tumours use to kill the T cells that attack them. It is in an early trial in people with advanced cancers.
Also called: GAMMA BIOTHERAPEUTICS, INC.
Overview
Gamma Biotherapeutics, Inc., of Portland, Oregon, is a private clinical-stage company developing therapeutics that help the immune system fight cancer. Its lead programme M3T01 is a monoclonal antibody that neutralises Fas ligand, which many tumours produce and which triggers apoptosis in activated T cells; the company describes it as the first FasL-neutralising antibody to enter clinical trials. M3T01 is being tested alone and with pembrolizumab and other systemic therapies in a phase 1 trial in advanced solid tumours (NCT06719362), sponsored by Providence Health & Services. In fiscal year 2026 the National Cancer Institute funded its SBIR project on the clinical development of M3T01 for advanced cancers (1R44CA310416-01, USD 979,068).
Headquarters
Portland, OR, US
Scorecard
All companies#717of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 1R44CA310416-01: Clinical development of the anti-fas ligand monoclonal antibody M3T01 for treatment of advanced cancers | 2026 | $979K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Products
1Phase 1Monoclonal antibody
M3T01 is an antibody from Gamma Biotherapeutics that blocks Fas ligand to protect cancer-fighting T cells, in a phase 1 trial in advanced solid tumours.
Notes
- Read on gammabiotherapeutics.com, ClinicalTrials.gov (NCT06719362) and the NIH RePORTER record on 4 November 2026. The first-in-clinic statement is the company's own. No Fas ligand target record exists in the corpus.
Connected
2fronts
drugs
Phase 1Monoclonal antibody
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
gammabiotherapeutics.com · 1
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/